Financial Highlights

Piramal Pharma Limited reported consolidated revenue of ₹2,270 crore for Q1 FY27, a 17% year‑on‑year increase from ₹1,934 crore in Q1 FY26. The CDMO segment contributed ₹1,187 crore (up 19% YoY), Complex Hospital Generics (CHG) ₹743 crore (up 17%), and Piramal Consumer Healthcare (PCH) ₹347 crore (up 15%). Other income rose 53% to ₹89 crore, bringing total income to ₹2,359 crore, an 18% rise.

Material cost increased 23% to ₹852 crore, employee expenses rose 9% to ₹676 crore, and other expenses grew 6% to ₹547 crore. EBITDA surged 72% to ₹285 crore, expanding the EBITDA margin from 8.5% to 12.5%, a gain of roughly 400 basis points driven by higher capacity utilization, pricing discipline and operational excellence. Interest expenses were ₹88 crore (up 2%), depreciation ₹224 crore (up 13%), and share of profit of associates ₹20 crore (up 5%).

Profit before tax recorded a loss of ₹7 crore, while tax expense was ₹62 crore, resulting in a net loss after tax of ₹69 crore, an improvement of 32% from the ₹102 crore loss in Q1 FY26. Exceptional items in Q1 FY26 included a one‑time insolvency proceeds of ₹21 crore; there were no exceptional items in Q1 FY27, so the net profit after tax after exceptional items remained ₹69 crore (15% better than the prior year).

Segment Highlights

  • CDMO: Growth was broad‑based across Indian and overseas sites, supported by a strengthened commercial team, healthy RFP activity and order inflows. Biopharma funding improvements increased RFPs, though decision timelines remain prolonged. The company inaugurated a commercial‑scale payload‑linker suite at Riverview (US) and kept the Lexington (US) sterile injectable capacity expansion on schedule. A strategic partnership with Ajinomoto Bio‑Pharma Services was announced for next‑gen conjugation technology.
  • Complex Hospital Generics (CHG): Retained a 48% value share in the US sevoflurane market and saw traction in select ex‑US inhalation‑anesthesia markets (IQVIA). Maintained #1 position in the US intrathecal baclofen market (IQVIA). Integration of Kenalog® is progressing, with supplies expected from Q2 FY27. Continued investments in 505(b)(2) products, complex generics, and co‑development activities.
  • Consumer Healthcare (PCH): Power Brands grew 23% YoY, accounting for 53% of PCH sales. E‑commerce grew 40% YoY, contributing 28% of sales. Launched the i‑choose master brand for women’s intimate care. Brand‑related media and trade promotion expenditures were approximately 12% of sales. Premiumisation, disciplined pricing and cost‑optimization mitigated raw‑material inflation, supporting EBITDA performance.

Quality and Regulatory Update

The Sellersville facility in the United States received an Establishment Inspection Report (EIR) from the US FDA, successfully concluding the inspection and maintaining the company’s Zero OAI (Observations, Adverse Findings, or Inspection) status to date.

Operational and Strategic Initiatives

  • ADC capabilities were enhanced with the commercial‑scale payload‑linker suite at Riverview (US). The Lexington (US) sterile injectable capacity expansion remains on track.
  • The commercial team across CDMO sites was expanded to improve market coverage and customer engagement.
  • Ongoing collaborations with suppliers aim to improve product availability for injectable pain‑management offerings.

Earnings Conference Call

Piramal Pharma will discuss the Q1 FY27 results on 30 July 2026 from 09:30 AM to 10:15 AM IST. Dial‑in numbers are provided for India, the USA, the UK, Singapore, and Hong Kong, with a registration link for Diamond Pass™ access.

About Piramal Pharma Limited

Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) operates a portfolio of differentiated products and services through 171 global development and manufacturing facilities and a distribution network in over 100 countries. The group comprises Piramal Pharma Solutions (CDMO), Piramal Critical Care (complex hospital generics), and Piramal Consumer Healthcare (OTC and wellness products). Associate companies include Abbvie Therapeutics India Private Limited (a joint venture with AbbVie) and a strategic minority stake in Yapan Bio Private Limited, which focuses on biologics, bio‑therapeutics, and vaccines.